Additionally, we observe inhibition of phospho ELK1 S383 at all time points and treatments, a mechanism previously shown to mediate sorafenib-induced endometrial carcinoma apoptosis by lowering MCL1 levels [33] (Figure 5A). Here, ELK1 is linked to endometrial carcinoma.